Actively Recruiting
Study on Effectiveness and Safety of LBBaP With Solia S and Selectra 3D Developed by BIOTRONIK
Led by Chinese Academy of Medical Sciences, Fuwai Hospital · Updated on 2024-08-26
1000
Participants Needed
1
Research Sites
93 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is aimed to assess the effectiveness and safety of LBBaP with Solia S and Selectra 3D in the Chinese population by analyzing the operation success rate and the system stability during follow-up visits.
CONDITIONS
Official Title
Study on Effectiveness and Safety of LBBaP With Solia S and Selectra 3D Developed by BIOTRONIK
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients receiving their first permanent pacemaker or cardiac resynchronization therapy implantation with planned LBBaP
- Willingness to participate in the study and sign the informed consent form
- Ability and willingness to attend all scheduled follow-up visits at the study sites
You will not qualify if you...
- Age under 18 years
- Presence of cardiac amyloidosis
- Ventricular hypertrophy with interventricular septum thickness ≥ 15 mm, or ≥ 13 mm if family history is present
- Participation in other interventional clinical trials
- Life expectancy less than one year
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanxi Cardiovascular Hospital
Taiyuan, Shanxi, China
Actively Recruiting
Research Team
C
Chen Keping, Doctor
CONTACT
L
Li Jie, Bachelor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here